Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea

Status Withdrawn

Clinical Trial Summary

This study is designed as a randomized double-blinded treatment trial among travelers' to geographical areas with moderate-severe rates of traveler's diarrhea. Travelers will be randomized to receive CBS 2004 or masked placebo to be taken daily while traveling. The test article or placebo will be taken starting 7 days prior to travel.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02736539
Study type	Interventional
Source	Clasado Biosciences Ltd
Contact
Status	Withdrawn
Phase	Phase 3
Start date	April 15, 2017
Completion date	February 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00672035` - Prevention, Randomized, Double-Blinded, Placebo-Controlled, Parallel Assignment, Safety/Efficacy Study	Phase 2
Completed	`NCT01208922` - Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea	Phase 3
Completed	`NCT01142089` - Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)	Phase 3
Not yet recruiting	`NCT04026984` - Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years	Phase 2
Not yet recruiting	`NCT04027894` - Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years	Phase 2
Completed	`NCT03866291` - ESBL in Patients Returning to Sweden With Traveller's Diarrhoea
Completed	`NCT03301103` - PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli	N/A
Completed	`NCT01040325` - Traveler's Diarrhea (TD) Vaccine Asia Efficacy Study	Phase 2